- Home
- JOF vs CLYM Comparison
JOF vs CLYM Comparison
Compare JOF & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JOF
- CLYM
- Stock Information
- Founded
- JOF 1990
- CLYM 2018
- Country
- JOF Japan
- CLYM United States
- Employees
- JOF N/A
- CLYM N/A
- Industry
- JOF Trusts Except Educational Religious and Charitable
- CLYM
- Sector
- JOF Finance
- CLYM
- Exchange
- JOF Nasdaq
- CLYM NYSE
- Market Cap
- JOF 220.2M
- CLYM 201.7M
- IPO Year
- JOF N/A
- CLYM 2021
- Fundamental
- Price
- JOF $7.69
- CLYM $1.94
- Analyst Decision
- JOF
- CLYM
- Analyst Count
- JOF 0
- CLYM 0
- Target Price
- JOF N/A
- CLYM N/A
- AVG Volume (30 Days)
- JOF 43.9K
- CLYM 479.0K
- Earning Date
- JOF 01-01-0001
- CLYM 03-27-2025
- Dividend Yield
- JOF 3.33%
- CLYM N/A
- EPS Growth
- JOF N/A
- CLYM N/A
- EPS
- JOF N/A
- CLYM N/A
- Revenue
- JOF N/A
- CLYM N/A
- Revenue This Year
- JOF N/A
- CLYM N/A
- Revenue Next Year
- JOF N/A
- CLYM N/A
- P/E Ratio
- JOF N/A
- CLYM N/A
- Revenue Growth
- JOF N/A
- CLYM N/A
- 52 Week Low
- JOF $6.64
- CLYM $1.73
- 52 Week High
- JOF $8.04
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- JOF 51.62
- CLYM N/A
- Support Level
- JOF $7.63
- CLYM N/A
- Resistance Level
- JOF $7.82
- CLYM N/A
- Average True Range (ATR)
- JOF 0.12
- CLYM 0.00
- MACD
- JOF 0.01
- CLYM 0.00
- Stochastic Oscillator
- JOF 64.47
- CLYM 0.00
About JOF Japan Smaller Capitalization Fund Inc
Japan Smaller Capitalization Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investments in smaller capitalization Japanese equity securities. Its portfolio of investments consists of different sectors such as banks, chemicals, construction, electric appliances, financing business, food, Information and Communication, Utilities, Real Estate, and others.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.